March 1
$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectSVI is an independent medical research institute that conducts research into the cause, prevention and treatment of diseases that are common and have serious effects on health. We strive, through our research, to help alleviate the enormous financial, emotional and physical impacts of these diseases on individuals, their families and the community.
ViewThe University of Queensland Diamantina Institute (UQDI) is a modern research facility where clinical and basic science converge in the translational research of cancer, immunology and genomic medicine. The Institute is host to over 300 researchers, students and support staff. It lays claim to global, world-changing discoveries such as the world’s first cervical cancer vaccine.
ViewSince 1998, the Harry Perkins Institute of Medical Research has grown to become one of the nation’s leading adult medical research centres, where a close-knit team of more than 400 research and trial staff work together to defeat the major diseases that impact our community. Our teams investigate a wide range of diseases, with a strong focus on cancer, cardiovascular disease, diabetes and neurogenetic diseases. Our world-class scientists, doctors and researchers are inspired to pursue vital research initiatives to build a healthier future for everyone.
Brandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read moreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Read more